

Elicera Therapeutics - On the right path

Redeye revisits some assumptions related to financing and likelihood of approval following the progress with the CARMA study and the recent share price development, leading to a raised valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Elicera Therapeutics - On the right path